Sugi Predict

Sugi Predict / Compounds / SCHEMBL4070432

SCHEMBL4070432

SCHEMBL4070432

O=C(Cc1ccc(F)cc1)NC(=S)Nc1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.62
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ CRHBP P24387 1/20 0.55
▸ CRHR2 Q13324 1/20 0.55
▸ RXFP1 Q9HBX9 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ RAB9A P51151 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.52
▸ MAPT P10636 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ MAPK1 P28482 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14096629 0.87 RAB9A (0.69) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL4074446 0.84 MET (0.56) GAAKMT2AMEN1CRHBPCRHR2
SCHEMBL15145925 0.80 LMNA (0.55) GAAKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL13926740 0.80 MET (0.55) GAAKMT2AMEN1CRHBPCRHR2
SCHEMBL1136788 0.80 SMN1; SMN2 (0.57) GAAKMT2AMEN1CRHBPCRHR2
SCHEMBL14839502 0.79 GAA (0.54) GAAKMT2AMEN1CRHBPCRHR2
SCHEMBL8014406 0.78 GAA (0.81) GAAKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL18031169 0.78 GAA (1.00) GAAKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL171965 0.77 LMNA (0.55) GAAKMT2AMEN1CRHBPCRHR2
SCHEMBL4335084 0.77 MET (0.67) GAAKMT2AMEN1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771177-A4 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-07-29 — — EP disclosed
EP-1761268-A4 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-07-08 — — EP disclosed
US-7439246-B2 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-10-21 — — US disclosed
US-7439246-B2 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-10-21 — — US disclosed
US-7439246-B2 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-10-21 — — US disclosed
US-7432373-B2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2008-10-07 — — US disclosed
US-7432373-B2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2008-10-07 — — US disclosed
US-7432373-B2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2008-10-07 — — US disclosed
CN-101027305-A Fused heterocyclic kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2007-08-29 — — CN disclosed
EP-1771177-A2 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-04-11 — — EP disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-20060211695-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 — — US disclosed
WO-2006004884-A2 PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
WO-2006004636-A2 FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
WO-2006004833-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
US-20060004006-A1 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-01-05 — — US disclosed
US-20050288290-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-29 — — US disclosed
US-20050288289-A1 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288290-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 GAA 1488/4885KMT2A 953/4885MEN1 1216/4885
US-20050288289-A1 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors MAP3K15, MAP4K2, MAP3K20 GAA 3388/4885KMT2A 1465/4885MEN1 1675/4885
US-20060004006-A1 Pyrrolotriazine kinase inhibitors MAP3K5, MAP3K15, MAP4K2 GAA 2824/4885KMT2A 785/4885MEN1 2112/4885
US-20060211695-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 GAA 1488/4885KMT2A 953/4885MEN1 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.